Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer

Abstract The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive bre...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hanne Vos, Kathleen Lambein, François Richard, Bram Mariën, Ines Nevelsteen, Kevin Punie, Hans Wildiers, Lieze Berben, Annouschka Laenen, Giuseppe Floris, Christine Desmedt, Ann Smeets
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Acceso en línea:https://doaj.org/article/8c78a70e9b4d4db798014a17106372d6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive breast cancer based on a selection of immune markers at the protein level in an institutional retrospective series. Additionally, we performed a similar comparison using publicly available transcriptomics data. Altogether, the results show a comparable TIME in both groups, with possible implications for the use of ICI in patients with hormone receptor-negative HER2-positive breast tumors.